Aneuploidy is associated with poor prognosis in solid tumors. Spontaneous chromosome missegregation events in aneuploid cells promote chromosomal instability (CIN) that may contribute to the acquisition of multidrug resistance in vitro and heighten risk for tumor relapse in animal models. Identification of distinct therapeutic agents that target tumor karyotypic complexity has important clinical implications. To identify distinct therapeutic approaches to specifically limit the growth of CIN tumors, we focused on a panel of colorectal cancer (CRC) cell lines, previously classified as either chromosomally unstable (CIN 
Introduction
Colorectal cancer (CRC) is associated with at least 2 distinct patterns of genomic instability (1) . The more common form of genomic instability in CRC is chromosomal instability (CIN), resulting in ongoing numerical and structural chromosomal aberrations in cancer cells, leading to intratumoral heterogeneity (2, 3) . The less common pattern is microsatellite instability (MIN) caused by a deficiency in the mismatch repair apparatus. Because of the accumulation of replication errors, MIN results in length variation of microsatellite sequences in DNA. Most MIN þ CRC cell lines are near-diploid (4, 5) and chromosomally stable (CIN À ). In contrast, CIN þ CRC cell lines are aneuploid and display a higher frequency of chromosomal missegregation errors during each mitosis relative to diploid cells (2) . In human CRC, CIN þ is widely inferred through the measurement of tumor DNA ploidy (6) ; normal diploid cells are defined with a DNA index of 1.0 (7) and thus an increase in DNA index infers polyploidy or aneuploidy. Approximately 25% of human CRC are both CIN À and MIN À (6).
Consistent molecular mechanisms responsible for the CIN þ phenotype and hence means to target this pattern of genome instability in colorectal and other solid tumors remain poorly defined. Putative mechanisms that may contribute to CIN include weakening of the spindle assembly checkpoint (SAC; refs. 8, 9) , defective sister chromatid cohesion (10) , merotelic sister chromatid attachments (11) , defective cytokinesis (12) , centrosome amplification (13) , and chromosome breakagefusion-bridge cycles (14) .
Increasing evidence suggests that CIN is associated with poor prognosis in solid tumors (6, 15, 16) . It has been suggested that adverse outcome associated with CIN may be related to increased tumor cell heterogeneity, driving the ability of tumors to adapt to environmental stresses (17) (18) (19) . Consistent with a hypothesis whereby CIN may enhance tumor adaptation, transient initiation of CIN, following the brief induction of MAD2 expression in activated KRASinitiated mouse lung tumor models, is associated with a high frequency of tumor recurrence following withdrawal of the KRAS oncogenic stimulus (20) . Preclinical studies have shown that CIN is associated with the rapid acquisition of multidrug resistance in cell line systems (21) and intrinsic taxane resistance in vitro and in vivo (22) . Recently, we and others have proposed the existence of a CIN survival phenotype that allows CIN þ tumor cells to tolerate the impact of excessive chromosome gains and losses (22) (23) (24) that may in turn impact upon altered drug sensitivity. Determining how CIN might impact upon prognosis and how this pattern of genomic instability might be specifically targeted remains an important research area (23, 25) . Evidence in lower eukaryotes has shown that aneuploid Saccharomyces cerevisiae are dependent on increased glucose utilization and are more sensitive to both heat shock protein 90 and proteosome inhibitors (26) . Polyploid S. cerevisiae are dependent upon increased expression of genes involved in sister chromatid cohesion and mitotic spindle function (27) . Roschke and Kirsch have shown the existence of anticancer compounds that may specifically target karyotypically complex cancer cells (25) . These observations indicate that karyotypic instability may be specifically targeted in eukaryotic organisms and suggest that CIN might be an exploitable and targetable phenotype in cancer.
To identify distinct therapeutic approaches to limit the growth of CIN þ tumors relative to diploid cells, we focused on a panel of CRC cell lines that had previously been classified as CIN þ or CIN À and used kinase inhibitor and cytotoxic libraries to identify agents that might be preferentially lethal toward CIN þ cells. Both isogenic and nonisogenic CIN þ cell lines displayed intrinsic multidrug resistance in vitro relative to CIN À cell lines. Importantly, consistent with the proposal that CIN þ is associated with intrinsic multidrug resistance, in a meta-analysis of patient outcome in CRC, CIN þ was associated with significantly worse clinical outcome relative to diploid cancers in both early-and late-stage disease following cytotoxic therapy.
Materials and Methods
Cell lines and FISH analysis 27 CRC cell lines (Table 1; Supplementary Table 1) , previously characterized for numerical/structural CIN, MIN status (2, (28) (29) (30) , and subject to Affymetrix SNP 6.0 Array analysis where available (20/27 cell lines; Wellcome Trust Sanger Institute), were used.
We used publicly available somatic mutation data from the Sanger Institute Cancer Cell Line Project (CLP) and COSMIC database (31 Cells were plated into 96-well tissue culture microplates at an initial seeding density of 4,000 cells per well. After 24 hours, cells were treated with the inhibitors at a final concentration of 10 mmol/L per well. This concentration was selected following drug titration test analysis to give an optimal range of mean relative surviving cells following inhibitor treatment across all cell lines. After 72 hours of treatment, cell viability was assayed using the Celltiter-Blue Cell Viability Assay (Promega) according to the manufacturer's instructions. The fluorescent readout for each inhibitor treated well was normalized to vehicle control wells. For the HCT116 MAD2 isogenic cell lines, a final inhibitor concentration of 1 mmol/L per well was used to allow for a larger range of surviving cells across all inhibitors.
5-Fluorouracil (5-FU) was used at both 1 and 10 mmol/L for a treatment length of 72 hours. The 27 CRC cell lines were plated and assayed using the same conditions and methods as described earlier.
Biolog Anti-Cancer Agent Microplate screen
Biolog Anti-Cancer Agent Microplates M11-M14 consisting of 92 anticancer agents at 4 increasing concentrations between 0.1 and 25 mmol/L per agent were used. Cells were plated at an initial seeding density of 5,000 cells per well. After 72 hours, the number of surviving cells per well was assayed using Biolog Redox Dye Mix MA according to manufacturer's instructions and normalized to the negative control wells.
Cell proliferation assay
We measured the proliferation rate of all 9 CIN À and 18 CIN þ CRC cell lines, using the IncuCyte Long-term Cell Imaging System. Cell lines were plated in 96-well plates at an initial plating density of 4,000 cells per well and phasecontrast images were obtained every 2 hours over 70 hours, allowing measurements of cell monolayer confluence. Outliers were removed manually, and growth curves were fitted by splines with the R package grofit (37) with smoothing parameter smooth.gc ¼ 0.7. 
Meta-analysis of clinical studies
Survival data were summarized using a log hazard ratio for comparison between CIN þ and CIN À groups. Data from individual studies were extracted using the methods described by Parmar and colleagues (38) and pooled to generate the summary statistic and CIs using a fixed-effects model with inverse variance weighting. All meta-analyses were performed using Stata 10.1 (Stata Corp).
Statistical methods
All tests were performed as 2-sided unless otherwise mentioned. To remove outliers, drugs resulting in relative number of cells greater than 1.4 were eliminated from analysis. A Kolmogorov-Smirnov test was performed to test for overall differences in the distribution of relative cell numbers following inhibitor treatment between CIN þ and CIN À cell lines.
Inhibitors that showed a fraction of surviving cells greater than 0.8 in more than 75% of the cell lines were excluded from the analysis. 
Results

Classification of CIN
þ cell lines and relationship with ploidy status and structural chromosomal complexity We selected 9 CIN À and 18 CIN þ CRC cell lines (Table 1) .
CIN status for these cell lines had been previously described in terms of numerical and structural chromosomal aberrations (2, (28) (29) (30) .
To confirm the utility of published approaches for defining the CIN status of the cell lines, where SNP Array data were available, we estimated the ploidy status of the cell lines by using weighted mean integer copy numbers derived from the PICNIC (Predicting Integral Copy Numbers In Cancer) algorithm (ref. 40 ; Fig. 1A Next, we addressed the relationship between CIN status and structural chromosomal complexity, using a summary structural chromosomal complexity score (SCCS) derived from the SNP Array data sets. This SCCS was determined by summarizing (i) the number of break points, (ii) LOH events as predicted using PICNIC (40) , and (iii) the Genome Integrity Index (GII; ref. 41 ) into a single value for each cell line (Fig. 1C) 2B ). These data suggest that at similar growth rates, CIN þ cell lines remain more drug resistant than CIN À cell lines, indicating that proliferation rate is unlikely to be the main determinant of drug sensitivity.
Somatic mutation status and drug sensitivity Next, we addressed whether distinct tumor cell line somatic mutations might be the underlying determinant of drug resistance rather than genomic instability status. We investigated whether the somatic mutation status of 20 genes (Table 1) was associated with altered sensitivity either to inhibitors grouped according to target kinase family (Aurora kinase, AKT, CDK, EGFR, FLT-3, GSK-3, JAK3, JNK, MEK, PDGFR, PI3K, and SYK) or to all inhibitors combined. We addressed whether there was an association of drug sensitivity with somatic mutation status in 13 genes for which cell line group sizes had sufficient statistical power to compare drug sensitivity in wild-type compared with mutated cell lines.
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on April 15, 2017. © 2011 American Association for Cancer cancerres.aacrjournals.org Downloaded from P ¼ 0.038, P ¼ 0.016, P ¼ 0.038, and P ¼ 0.004, respectively; Supplementary Fig. 3B ]. We found no evidence for a specific association with either PIK3CA exon 9 or 20 mutation status and drug sensitivity (data not shown). Notably, PIK3CA mutations were more likely to occur in CIN À than in CIN þ cell lines (P ¼ 0.0066, Fisher's exact test). No single somatic mutation was associated with altered sensitivity to all inhibitors. Next, data for somatic mutation status and CIN status were pooled. When corrected for multiple testing by the Benjamini-Hochberg method under the assumption that the tests are either positively correlated or independent (45), CIN þ status was the only parameter significantly associated with multidrug resistance (corrected P ¼ 0.01; Supplementary Fig. 3B ). Taken together, these data suggest that the association of PIK3CA mutation with CIN À status may confound the interpretation of the association of PIK3CA mutation status with sensitivity to specific inhibitors and may simply reflect the intrinsic drug sensitivity of CIN À cells.
Isogenic CIN þ CRC cell lines display intrinsic multidrug resistance
To support a direct role for the contribution of CIN to the multidrug-resistant phenotype, we assessed whether drug sensitivity was altered in isogenic CRC models of CIN. The HCT116 MAD2 þ/À cell line has one allele of the SAC gene, MAD2, deleted by homologous recombination, resulting in numerical CIN relative to its diploid parental cell line (9) . We treated the isogenic HCT116 MAD2 þ/À cell and its parental diploid cell line with the kinase inhibitors and assessed the surviving cell line fraction after treatment. Consistent with the nonisogenic cell line data presented previously, the MAD2 þ/À cell line was found to be more resistant overall to the inhibitors tested than to the parental diploid cell line (onesided Wilcoxon signed-rank test, P ¼ 0.001; Fig. 3A ) to a diverse range of anticancer agents than to the parental diploid cell lines ( Fig. 3C and D) .
Importantly, both the HCT116 MAD2 þ/À and parental diploid cell lines continue to display MIN þ ( Supplementary   Fig. 4 Fig. 4C ). This implies that karyotypic heterogeneity, rather than increased ploidy, might be responsible for increased drug resistance compared with karyotypically stable diploid cells. We cannot formally exclude the possibility that acquired mutations present in the drug-resistant tetraploid clone that may have permitted the spontaneous tetraploid phenotype may primarily be responsible for increased drug resistance. Taken together with the isogenic cell line data sets presented here, where CIN is artificially induced through loss of one allele of MAD2 or both copies of PTTG1, these results support the contribution of CIN, rather than increased ploidy status or MIN, in conferring altered drug sensitivity.
Relationship between CIN status and benefit from cytotoxic therapy in clinical datasets
Published Fig. 6A, B) . Next, we asked whether CIN þ status might be associated with poorer outcome following adjuvant therapy with 5-FUbased regimens. A meta-analysis of studies examining the relationship between CIN and prognosis in locoregional CRC, revealed that CIN þ disease (defined as aneuploidy/polyploidy determined using flow cytometry) confers a worse overall survival (30 studies) ( Supplementary Fig. 5A ) and Fisher's exact test, P = 0.05 TC4 Figure 4 . A, boxplot of relative surviving cell numbers comparing HCT116 TC4 and DC8 cell lines and TC9 with DC8 cell lines. The TC9 cell line was significantly more resistant than DC8 (P < 0.001). The difference in drug sensitivity between TC4 and DC8 was not significant (P ¼ 0.078 (Fig. 5A) . Two studies explore the predictive value of CIN (46, 48) in patients with locoregional CRC who received either adjuvant chemotherapy or no chemotherapy following surgery (Fig. 5B) . Patients with diploid CRC seem to benefit from 5-FU-based therapy (N ¼ 262, HR ¼ 0.61; 95% CI ¼ 0.40-0.94, P ¼ 0.024; I 2 ¼ 0%, P ¼ 0.467) compared with untreated diploid controls, whereas there was no significant difference between treated and untreated CIN þ CRCs (N ¼ 303, HR ¼ 0.81; 95% CI ¼ 0.57-
The combined analysis of all patients suggests a benefit following 5-FU treatment comparable with that reported in the literature for genetically unselected patients (49) . While these studies are limited, they are consistent with the view that patients with CIN þ CRC derive less benefit from 5-FU-based adjuvant cytotoxic chemotherapy than patients with diploid CRC. Prospective evaluation of the association of CIN þ disease with the efficacy of combination regimens (e.g., 5-FU/oxaliplatin) in stage 3 and 5-FU/oxaliplatin and irinotecan in stage 4 disease might be considered to assess whether clinical outcome following these more recent regimens has a similar association with CIN status. Stratifying drug response according to CIN status may limit the risk of early drug attrition and heighten the chance of identifying responder populations in patients with diploid tumors. Importantly, these data indicate that specifically targeting cancer cells with CIN þ status, using currently available kinase inhibitors, seems challenging. An improved understanding of the mechanisms associated with the generation and survival of CIN þ CRC will be important to drive the development of new therapeutic approaches in order to improve patient outcome in this high-risk disease subtype.
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